Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Operations: 2014-2025

Historic Cash from Operations for vTv Therapeutics (VTVT) over the last 11 years, with Sep 2025 value amounting to -$5.2 million.

  • vTv Therapeutics' Cash from Operations rose 18.64% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.8 million, marking a year-over-year increase of 10.97%. This contributed to the annual value of -$25.3 million for FY2024, which is 32.63% down from last year.
  • According to the latest figures from Q3 2025, vTv Therapeutics' Cash from Operations is -$5.2 million, which was down 2.49% from -$5.1 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Cash from Operations ranged from a high of $706,000 in Q2 2022 and a low of -$8.8 million during Q3 2022.
  • Over the past 3 years, vTv Therapeutics' median Cash from Operations value was -$5.2 million (recorded in 2025), while the average stood at -$5.5 million.
  • In the last 5 years, vTv Therapeutics' Cash from Operations spiked by 117.66% in 2022 and then tumbled by 973.51% in 2023.
  • Quarterly analysis of 5 years shows vTv Therapeutics' Cash from Operations stood at -$6.4 million in 2021, then decreased by 7.22% to -$6.9 million in 2022, then surged by 57.65% to -$2.9 million in 2023, then tumbled by 65.58% to -$4.8 million in 2024, then rose by 18.64% to -$5.2 million in 2025.
  • Its Cash from Operations stands at -$5.2 million for Q3 2025, versus -$5.1 million for Q2 2025 and -$5.7 million for Q1 2025.